GW433908: Phase III

In the Phase III NEAT and SOLO trials, GW433908 met the endpoints at 48 weeks. The companies' Phase III CONTEXT trial of GW433908 met its endpoints at 24 weeks. Last month, 24-week NEAT data that show...